| Literature DB >> 34924002 |
Yosef Zenebe1, Baye Akele2, Mulugeta W/Selassie3, Mogesie Necho4.
Abstract
BACKGROUND: Ethiopia, being in the Sub Saharan region of Africa, is one of the countries with a substantial burden of HIV infection. Because of the high burden of HIV and poor health care settings, HAND is prevalent as demonstrated in various cross-sectional studies. However, no review has been conducted to report the consolidated magnitude of HAND among people with HIV in Ethiopia. Therefore, this systematic review and meta-analysis aimed to estimate the prevalence of HAND in Ethiopia.Entities:
Keywords: Ethiopia; HAND; HIV/AIDS; Systematic review
Mesh:
Year: 2021 PMID: 34924002 PMCID: PMC8684693 DOI: 10.1186/s12981-021-00424-1
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Fig. 1Flow diagram of included studies
The characteristics of studies included in the systematic review and meta-analysis of HAND in Ethiopia
| Author, publication year | Location of the study | Study setting | Study design | Sample size | Tool used | Prevalence | Number of cases |
|---|---|---|---|---|---|---|---|
| Belete et al. 2017 | Mekelle, Ethiopia | Health institution | CS | 254 | IHDS ≤ 9.5 | 33.3% | 85 |
| Tsegaw et al. 2017 | South Wollo, Ethiopia | Health institution | CS | 593 | IHDS ≤ 9.5 | 36.4% | 216 |
| Animut et al. 2019 | Gamo Gofa, Ethiopia | Health institution | CS | 684 | IHDS < 9.5 | 67.1% | 459 |
| Araya et al. 2020 | Addis Ababa, Ethiopia | Health institution | CS | 581 | IHDS ≤ 9.5 | 35.6% | 207 |
| Yitbarek et al. 2019 | Jimma, Ethiopia | Health institution | CS | 328 | IHDS ≤ 10 | 35.7% | 117 |
| Mossie et al. 2014 | Debre Markos, Ethiopia | Health institution | CS | 423 | IHDS ≤ 10 | 24.8% | 105 |
| Wubetu et al. 2021 | Debre Berhan, Ethiopia | Health institution | CS | 422 | MMSE < 25 | 41% | 173 |
| Salahuddin et al. 2020 | Mizan-Aman, Ethiopia | Health institution | CS | 244 | IHDS ≤ 10 | 39.3% | 96 |
CS cross-sectional, HAND HIV Associated Neurocognitive Disorders, IHDS International HIV Dementia Scale, MMSE Mini Mental State Examination
Qualities of studies included in the systematic review and meta-analysis
| Study name | Response | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Total | |
| Belete et al. 2017 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Tsegaw et al. 2017 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Animut et al. 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Araya et al. 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Yitbarek et al. 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Mossie et al. 2014 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Wubetu et al. 2021 | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9 |
| Salahuddin et al. 2020 | Y | N | U | Y | Y | Y | Y | Y | Y | 7 |
Q1–Q9 represents questions used to assess the quality of included studies, which are listed below
Q1. Was the sample frame appropriate to address the target populations?
Q2. Were the study participants sampled in appropriate way?
Q3. Was the sample size adequate?
Q4. Were the study subjects and setting described in details?
Q5. Was the data analysis conducted with sufficient coverage of the identified sample? Q6. Was a valid method used in the identification of conditions?
Q7. Was the condition measured in a standard, reliable way for all participants?
Q8. Was there an appropriate statistical analysis?
Q9. Was the response rate adequate, and if not, was the low response rate managed appropriately?
N no, NA not applicable, U unclear, Y yes
Fig. 2The forest plot of the prevalence of HAND among People with HIV in Ethiopia: a meta-analysis
A subgroup analysis among people living with HIV
| Subgroup | Number of studies | Estimates | Heterogeneity | ||
|---|---|---|---|---|---|
| Prevalence (%) | 95% CI | I 2 | P-value | ||
| Year of publication | |||||
| 2014–2017 Years | 3 | 31.50 | 24.32, 38.68 | 100% | < 0.001 |
| 2019–2021 Years | 5 | 43.74 | 30.32, 57.16 | 100% | < 0.001 |
| Location of the study | |||||
| Amhara | 3 | 34.07 | 25.39, 42.74 | 100% | < 0.001 |
| SNNPR | 2 | 53.20 | 25.96, 80.44 | 100% | < 0.001 |
| Others (Tigray, Addis Ababa and Oromia) | 3 | 34.87 | 33.49, 36.24 | 99.2% | < 0.001 |
| Sample size | |||||
| Below 400 | 3 | 36.10 | 32.83, 39.37 | 99.8% | < 0.001 |
| Above 400 | 5 | 40.98 | 26.64, 55.32 | 100% | < 0.001 |
Fig. 3Sensitivity analysis for the prevalence of HAND among people with HIV in Ethiopia
Fig. 4Funnel plot of standard error by logit event rate (publication bias)
A systematic review and meta-analysis of associated factors for HAND in Ethiopia
| Associated factors | Odds ratio(AOR) | 95% confidence interval | Strength of association | Author, year of publication |
|---|---|---|---|---|
| Older age | 3.31 | 1.26, 8.70 | Strong and positive | Tsegaw et al. 2017 |
| Age group of 41–64 years | 3.1 | 1.3, 7.4 | Strong and positive | Yitbarek et al. 2019 |
| Older age of 50 years or above | 4.25 | 1.05, 17.18 | Strong and positive | Mossie et al. 2014 |
| Older individuals | 1.06 | 1.03, 1.08 | Weak and positive | Wubetu et al. 2021 |
| Being older than 40 years | 2.81 | 1.11, 7.15 | Moderate and positive | Salahuddin et al. 2020 |
| No formal education | 4.29 | 2.62, 7.02 | Strong and positive | Tsegaw et al. 2017 |
| Being illiterate | 5.16 | 2.20, 12.07 | Strong and positive | Araya et al. 2020 |
| Having no education | 3.11 | 1.37, 7.04 | Strong and positive | Mossie et al. 2014 |
| Having a primary-level education | 3.27 | 1.46, 7.29 | Strong and positive | Araya et al. 2020 |
| Being married | 0.377 | 0.21, 0.67 | Weak and negative | Animut et al. 2019 |
| Unemployment status | 3.18 | 1.75, 5.78 | Strong and positive | Animut et al. 2019 |
| Low monthly income | 4.22 | 2.02, 8.81 | Strong and positive | Wubetu et al. 2021 |
| Body mass index 16 kg/m2 | 4.39 | 1.60, 12.02 | Strong and positive | Animut et al. 2019 |
| Having poor social support | 3.65 | 1.86, 7.17 | Strong and positive | Wubetu et al. 2021 |
| Poor medication adherence | 1.49 | 1.01, 2.18 | Weak and positive | Tsegaw et al. 2017 |
| Being non-compliant with prescribed medications | 2.99 | 1.01, 8.87 | Moderate and positive | Salahuddin et al. 2020 |
| Lifetime use of tobacco | 2.40 | 1.44, 4.01 | Moderate and positive | Araya et al. 2020 |
| Khat chewing | 4.4 | 2.3, 8.3 | Strong and positive | Yitbarek et al. 2019 |
| Substance use | 4.64 | 2.3, 9.36 | Strong and positive | Mossie et al. 2014 |
| Having a history of recreational drug use | 13.67 | 6.42, 29.13 | Strong and positive | Salahuddin et al. 2020 |
| CD4 count of 500 cells/dl or less | 2.37 | 1.52, 3.68 | Moderate and positive | Tsegaw et al. 2017 |
| Having a CD4 count (cells/μl) ≤ 500 | 1.61 | 1.11, 2.39 | Weak and positive | Araya et al. 2020 |
| Plasma HIV-1 RNA load between 1.7log10 and 3log10 copies/ml | 2.2 | 1.1, 4.3 | Moderate and positive | Yitbarek et al. 2019 |
| ≥ 3log10 copies/ml | 7.5 | 2.6, 21.5 | Strong and positive | Yitbarek et al. 2019 |
| Impairment in the activity of daily living | 7.19 | 1.73, 21.83 | Strong and positive | Belete et al. 2017 |
| Have no communication about safe sexual intercourse | 2.88 | 1.61, 5.16 | Moderate and positive | Wubetu et al. 2021 |
| Having co-morbid opportunistic infection | 7.48 | 4.1, 13.64 | Strong and positive | Mossie et al. 2014 |
| Having comorbid depression and anxiety | 5.51 | 1.81, 16.79 | Strong and positive | Wubetu et al. 2021 |
| Higher duration of HIV illness | 1.01 | 1.001, 1.02 | Weak and positive | Wubetu et al. 2021 |
| Late clinical stage of the illness | 4.2 | 1.19, 14.44 | Strong and positive | Belete et al. 2017 |
| Advancing stages of the disease | 3.558 | 1.41, 9.01 | Strong and positive | Animut et al. 2019 |
| Clinical stage III of the disease | 5.6 | 1.7, 19.2 | Strong and positive | Yitbarek et al. 2019 |
Pooled odds ratio of HAND among people with HIV
| Factors | Estimates | Heterogeneity | Studies pooled | ||
|---|---|---|---|---|---|
| Pooled effect size | 95% CI | I 2 | P-value | ||
| Older age | 2.97 | 2.12, 3.82 | 89.9% | < 0.001 | [ |
| Being illiterate | 4.20 | 3.12, 5.28 | 94.7% | < 0.001 | [ |
| Substance abuse | 6.28 | 0.73, 11.82 | 99.8% | < 0.001 | [ |
| Advanced stages of the diseases | 4.45 | 3.16, 5.74 | 95.2% | < 0.001 | [ |